Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in Parkinson’s disease. Metabolon, Inc. has announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback